Skip to main content

Table 2 Comparison between the clinically improved and clinically non-improved groups as regards IGFBP1 and IGFBP2 in serum and BAL, 6MWT, and SPaO2

From: Non-invasive IGFBP1, IGFBP2 biomarkers as predictors and outcomes of usual interstitial pneumonia (UIP) therapeutic response

Parameters

Clinically improved (n = 14), mean ± SD

Clinically non-improved (n = 9), mean ± SD

T test

P value

IGFBP1 in serum (mmol/l)

266.9 ± 28.6

243.7 ± 37.8

1.66

0.1

IGFBP2 in serum (mmol/l)

179.7 ± 39.9

193.1 ± 33.4

− 0.82

0.4

IGFBP1 in BAL (mmol/l)

229.3 ± 31.5

209.8 ± 21.6

1.61

0.1

IGFBP2 in BAL (mmol/l)

148.5 ± 28.5

151.3 ± 17.1

− 0.26

0.7

6MWT

246.8 ± 13.3

169.5 ± 20.2

11.06

0.000*

SPaO2

92.0 ± 1.4

83.3 ± .5

16.8

0.000*

  1. IGFBP1 insulin-like growth factor binding protein 1, IGFBP2 insulin-like growth factor binding protein 2, BAL bronchoalveolar lavage, 6MWT 6 min walking test, SPaO2 O2 saturation
  2. *The level of significance was accepted at p ≤ 0.05